Digital booklet gmhsummit 18

SYMPOSIUM. BENIGN PROSTATIC HYPERPLASIA (BPH). WHAT LIES AHEAD? Epidemiology and evaluation.  Guidelines for the diagnosis of lower urinary tract symptoms in men.  BPH and PSA: Correlation and management.  Nocturia: advances in diagnosis and treatment.  BPH: Guidelines for Medical Management and alternative therapies.  • Effect of 5α-Reductase inhibitors in the BPH. Erectile dysfunction (ED) associated syndrome.  Tadalafil alone or combined to manage BPH: The new frontier?  Phytotherapy and BPH  Surgical Treatment: New minimal invasive technologies.  HoLEP vs Greenlight Laser.  Laser therapy: enucleation vs vaporization. 

Evaluation and management of Uro- Genital pain.  Interstitial Cystitis and Bladder pain Syndrome: is a problem for men too.  Urodynamics: dynamic study, evolving and subject to interpretation.  Evaluation and management of neurogenic bladder in adults.  Contemporary Pharmacotherapy of the Overactive Bladder.  Is Sacral Neuromodulation the best alternative?  BotulinumToxin:whentouseit, for whatdoyouuseitandwhicharethe outcomes.  Pollen extract with vitamins vs Serenoa Repens in chronic prostatitis and chronic pelvic pain syndrome. 

SYMPOSIUM. PROSTATITIS, CHRONIC PELVIC PAIN, HYPERACTIVE BLADDER.

Urinary tract infections: Emerging Processes and Clinical Guidelines.  Chronic nonbacterial prostatitis: where are we?  Chronic prostatitis in the patient with prostate cancer.  The role of uncommon bacteria in chronic prostatitis and chronic pelvic pain syndrome. 

SYMPOSIUM. I PROSTATE CANCER: EPIDEMIOLOGY, NATURAL HISTORY, DETECTION, STAGING AND PROGNOSIS.

Vaccines against Prostate Cancer, current state of research.  Selective Androgen Receptor Modulators (SARMS): current status report. 

Made with FlippingBook flipbook maker